The Risk of Cancer Associated With the Use of Abatacept and Other Biologic Agents Among Rheumatoid Arthritis Patients
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 31 Dec 2018
Price : $35 *
At a glance
- Drugs Abatacept (Primary) ; Tumour necrosis factor inhibitors
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 18 Dec 2018 Planned End Date changed from 31 Dec 2018 to 29 Mar 2019.
- 18 Dec 2018 Planned primary completion date changed from 31 Dec 2018 to 29 Mar 2019.
- 20 Sep 2018 New trial record